GeneTether Therapeutics, Inc. (TSE:GTTX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GeneTether Therapeutics Inc. has disclosed its financial figures for the first quarter of 2024, revealing total assets of $1.254 million and a net loss of $144,000. The company, known for its proprietary DNA insertion technology, has downscaled its platform development and is exploring strategic options to enhance shareholder value. Investors and stakeholders can access the complete financial details on the SEDAR+ website.
For further insights into TSE:GTTX stock, check out TipRanks’ Stock Analysis page.